Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,765 | 112 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $346.72 | 21 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $317.77 | 19 | $0 (2024) |
| ABBVIE INC. | $222.76 | 11 | $0 (2023) |
| Novo Nordisk Inc | $177.52 | 26 | $0 (2023) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $140.16 | 6 | $0 (2023) |
| PFIZER INC. | $133.33 | 7 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $65.06 | 3 | $0 (2023) |
| Daiichi Sankyo Inc. | $55.16 | 2 | $0 (2024) |
| Esperion Therapeutics, Inc. | $50.49 | 3 | $0 (2023) |
| GlaxoSmithKline, LLC. | $47.89 | 3 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $205.10 | 10 | AstraZeneca Pharmaceuticals LP ($72.59) |
| 2023 | $307.22 | 17 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($52.73) |
| 2022 | $710.35 | 56 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($188.45) |
| 2021 | $541.97 | 29 | AstraZeneca Pharmaceuticals LP ($137.08) |
All Payment Transactions
112 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $24.20 | General |
| Category: Gastroenterology | ||||||
| 11/21/2024 | PFIZER INC. | PREVNAR 20 (Biological), ABRYSVO | Food and Beverage | In-kind items and services | $26.44 | General |
| Category: VACCINES | ||||||
| 10/24/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $16.16 | General |
| Category: RESPIRATORY | ||||||
| 10/09/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $23.15 | General |
| Category: Respiratory | ||||||
| 09/23/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $23.83 | General |
| Category: Gastroenterology | ||||||
| 09/20/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $16.95 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/11/2024 | PFIZER INC. | PREVNAR 20 (Biological), ABRYSVO | Food and Beverage | In-kind items and services | $13.21 | General |
| Category: VACCINES | ||||||
| 08/30/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $16.59 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 08/13/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $15.90 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 08/08/2024 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $28.67 | General |
| Category: Iron Deficiency Anemia | ||||||
| 12/14/2023 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $16.72 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 12/07/2023 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $26.49 | General |
| Category: Iron Deficiency Anemia | ||||||
| 09/13/2023 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $15.21 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 08/31/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $14.86 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 08/17/2023 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $15.75 | General |
| Category: Obesity | ||||||
| 07/06/2023 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Food and Beverage | In-kind items and services | $18.16 | General |
| Category: Neuroscience | ||||||
| 06/01/2023 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $18.56 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 05/22/2023 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $15.06 | General |
| Category: Gastroenterology | ||||||
| 05/19/2023 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $17.82 | General |
| Category: Cardio-renal | ||||||
| 04/13/2023 | PFIZER INC. | NURTEC ODT (Drug) | Food and Beverage | In-kind items and services | $15.18 | General |
| Category: PAIN | ||||||
| 04/05/2023 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $22.65 | General |
| Category: Gastroenterology | ||||||
| 03/21/2023 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $20.07 | General |
| Category: NEUROSCIENCE | ||||||
| 03/16/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $17.89 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 03/10/2023 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Food and Beverage | In-kind items and services | $21.57 | General |
| Category: Neuroscience | ||||||
| 02/02/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $19.32 | General |
| Category: DIABETES | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2020 | 44 | 4,775 | 12,405 | $1.3M | $341,709 |
All Medicare Procedures & Services
44 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 915 | 1,823 | $381,357 | $133,870 | 35.1% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2020 | 501 | 501 | $109,186 | $51,593 | 47.3% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 646 | 991 | $149,173 | $47,891 | 32.1% |
| 90662 | Vaccine for influenza for injection into muscle | Office | 2020 | 287 | 287 | $26,787 | $17,501 | 65.3% |
| 99496 | Transitional care management services, highly complexity, requiring face-to-face visits within 7 days of discharge | Office | 2020 | 82 | 94 | $42,629 | $16,344 | 38.3% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 90 | 137 | $18,231 | $10,208 | 56.0% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 68 | 68 | $24,212 | $7,006 | 28.9% |
| G0008 | Administration of influenza virus vaccine | Office | 2020 | 308 | 308 | $11,435 | $5,445 | 47.6% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 55 | 61 | $15,948 | $4,702 | 29.5% |
| G0446 | Annual, face-to-face intensive behavioral therapy for cardiovascular disease, individual, 15 minutes | Office | 2020 | 180 | 180 | $8,424 | $4,171 | 49.5% |
| 90670 | Pneumococcal vaccine for injection into muscle | Office | 2020 | 34 | 34 | $3,785 | $3,738 | 98.8% |
| 83036 | Hemoglobin a1c level | Office | 2020 | 224 | 326 | $15,630 | $3,153 | 20.2% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 22 | 22 | $10,036 | $2,895 | 28.8% |
| G0444 | Annual depression screening, 15 minutes | Office | 2020 | 177 | 177 | $5,907 | $2,887 | 48.9% |
| G0442 | Annual alcohol misuse screening, 15 minutes | Office | 2020 | 170 | 170 | $5,687 | $2,773 | 48.8% |
| 90732 | Vaccine for pneumococcal polysaccharide for injection beneath the skin or into muscle, patient 2 years or older | Office | 2020 | 25 | 25 | $2,840 | $2,659 | 93.6% |
| 99495 | Transitional care management services, moderately complexity, requiring face-to-face visits within 14 days of discharge | Office | 2020 | 17 | 17 | $5,432 | $2,239 | 41.2% |
| 20610 | Aspiration and/or injection of large joint or joint capsule | Office | 2020 | 37 | 47 | $5,389 | $2,008 | 37.3% |
| G0180 | Physician certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians to affirm the initial implem | Office | 2020 | 50 | 51 | $6,681 | $1,934 | 29.0% |
| G0402 | Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment | Office | 2020 | 13 | 13 | $4,177 | $1,917 | 45.9% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2020 | 81 | 177 | $6,167 | $1,786 | 29.0% |
| 17004 | Destruction of 15 or more skin growths | Office | 2020 | 14 | 14 | $4,064 | $1,519 | 37.4% |
| 17000 | Destruction of skin growth | Office | 2020 | 26 | 28 | $3,532 | $1,290 | 36.5% |
| 99212 | Established patient office or other outpatient visit, typically 10 minutes | Office | 2020 | 39 | 40 | $3,604 | $1,229 | 34.1% |
| G0181 | Physician supervision of a patient receiving medicare-covered services provided by a participating home health agency (patient not present) requiring complex and multidisciplinary care modalities involving regular physician development and/or revision of c | Office | 2020 | 14 | 15 | $2,880 | $1,140 | 39.6% |
About Will Nesbitt
Will Nesbitt is a Family Medicine healthcare provider based in Redding, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/21/2018. The National Provider Identifier (NPI) number assigned to this provider is 1184101206.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Will Nesbitt has received a total of $1,765 in payments from pharmaceutical and medical device companies, with $205.10 received in 2024. These payments were reported across 112 transactions from 18 companies. The most common payment nature is "Food and Beverage" ($1,765).
As a Medicare-enrolled provider, Nesbitt has provided services to 4,775 Medicare beneficiaries, totaling 12,405 services with total Medicare billing of $341,709. Data is available for 1 year (2020–2020), covering 44 distinct procedure/service records.
Practice Information
- Specialty Family Medicine
- Location Redding, CA
- Active Since 07/21/2018
- Last Updated 11/18/2020
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1184101206
Products in Payments
- XIFAXAN (Drug) $346.72
- FARXIGA (Drug) $229.35
- Rybelsus (Drug) $132.52
- UBRELVY (Drug) $124.64
- JARDIANCE (Drug) $109.26
- VRAYLAR (Drug) $98.12
- PREVNAR 20 (Biological) $76.36
- SPRAVATO (Drug) $65.06
- INJECTAFER (Drug) $55.16
- NURTEC ODT (Drug) $54.53
- NEXLETOL (Drug) $50.49
- TRELEGY ELLIPTA (Drug) $47.89
- BREZTRI (Drug) $35.57
- Aimovig (Biological) $35.47
- Ozempic (Drug) $29.25
- SPIRIVA RESPIMAT (Drug) $28.67
- TRINTELLIX (Drug) $25.79
- PREVNAR 13 (Biological) $23.48
- HETLIOZ (Drug) $23.27
- AIRSUPRA (Drug) $23.15
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Redding
Jack Finch, M.d, M.D
Family Medicine — Payments: $22,124
Andrew Solkovits, D.o, D.O
Family Medicine — Payments: $21,525
Sheila Finch, Md, MD
Family Medicine — Payments: $17,649
Dr. Paul Davis, D.o, D.O
Family Medicine — Payments: $9,814
James Mu, M.d, M.D
Family Medicine — Payments: $6,276
Richard Martinez, Md, MD
Family Medicine — Payments: $6,033